hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06264661 id: HJM 006/22-R briefTitle: Effect of Cognitive Behavioral Therapy and Phototherapy on Glycosylated Hemoglobin, CLOCK Genes and Quality of Life in Patients With Type 2 Diabetes Mellitus and Insomnia overallStatus: COMPLETED date: 2022-08-08 date: 2022-09-30 date: 2022-11-30 date: 2024-02-20 date: 2024-02-20 name: Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás class: OTHER briefSummary: Purpose: To analyze the efficiency of Cognitive Behavioral Intervention in combination with phototherapy to reduce insomnia and improve glycemic control, quality of life, and CLOCK genes expression in patients with type 2 diabetes mellitus. Methods: Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried out with validated instruments for Mexican population and gene expression was evaluated by real-time PCR. conditions: Type 2 Diabetes studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: SINGLE_GROUP interventionModelDescription: Clinical, quasi-experimental, pre-post, explanatory, non-probability sampling. Subjects were invited to participate in Hospital Juárez de México. They received eight sessions of Cognitive Behavioral Therapy in combination with phototherapy. The assessment was carried outwith validated instruments for Mexican population and gene expression was evaluated by real-time PCR. primaryPurpose: TREATMENT masking: NONE count: 23 type: ACTUAL name: Effect of Cognitive Behavioral Therapy with Phototherapy in glycated hemoglobin, CLOCK genes and quality of life in patients with type 2 diabetes mellitus and insomnia measure: Sleep quality measure: Glycosylated hemoglobin measure: Quality of life measure: Insomnia measure: Gene expression analysis of CLOCK measure: Gene expression analysis of BMAL1 measure: Gene expression analysis of PER1 measure: Gene expression analysis of PER2 sex: ALL minimumAge: 40 Years maximumAge: 60 Years stdAges: ADULT facility: Centro Interdisciplinario de Ciencias de la Salud Unidad Santo Tomás city: Cdmx state: México zip: 11360 country: Mexico hasResults: False
nctId: NCT06264648 id: AIBU-FTR-OOP-04 briefTitle: Investigation of Palpation Pressure Sensitivity overallStatus: COMPLETED date: 2023-05-03 date: 2023-06-16 date: 2023-10-20 date: 2024-02-20 date: 2024-02-20 name: Abant Izzet Baysal University class: OTHER briefSummary: The study is planned for searching physiotherapists palpation abilities. There were 2 groups of physiotherapists. They were asked for to push target pressures. After making some exercise, the assesment was done again. conditions: Sensitivity Training Groups studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: 2 groups of physiotherapists with different fields of experience were attended to study. primaryPurpose: OTHER masking: NONE count: 63 type: ACTUAL name: Pressure sensitivity education measure: Measurement Palpation Pressure with Digital Scale measure: Measurement Palpation Pressure with Digital Scale sex: ALL minimumAge: 22 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Faculty of Health Sciences Bolu Abant İzzet Baysal University city: Bolu zip: 14300 country: Turkey lat: 40.73583 lon: 31.60611 hasResults: False
nctId: NCT06264635 id: HS26227 briefTitle: Evaluating the Efficacy of Platelet-Rich-Plasma (PRP) for Erectile Dysfunction overallStatus: NOT_YET_RECRUITING date: 2024-03 date: 2025-03 date: 2025-03 date: 2024-02-20 date: 2024-03-08 name: University of Manitoba class: OTHER briefSummary: There is great interest in restorative therapies (platelet-rich plasma (PRP) injections, shockwave therapy and stem cell therapy) for ED given their non-invasive nature. However, data is still limited and requires further research prior to widespread adoption. Unfortunately, therapies such as PRP injections are being widely used without clinical evidence demonstrating its safety or effectiveness for the treatment of erectile dysfunction. 2-7 To date, there are no treatments that address the underlying cause of endothelial dysfunction, although low-intensity shockwave therapy for ED has shown promising results. Platelet-derived therapies targeting inflammation and promoting tissue/nerve regeneration and may represent a potential treatment option towards this direction. The investigators propose to perform Canada's first pilot RCT to evaluate and safety and efficacy of PRP for the treatment of ED. conditions: Erectile Dysfunction studyType: INTERVENTIONAL phases: PHASE1 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE maskingDescription: The provider and patient are both blinded to which treatment (PRP vs saline) the patient is receiving whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 60 type: ESTIMATED name: Platelet-Rich-Plasma name: Saline measure: International Index of Erectile Function (IIEF) measure: Adverse Events sex: MALE minimumAge: 30 Years maximumAge: 70 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Men's Health Clinic city: Winnipeg state: Manitoba zip: R3K 1M3 country: Canada name: Premal Patel, MD role: CONTACT phone: 2042214476 email: ppatel5@hsc.mb.ca name: Jainik Shah, BFSc role: CONTACT phone: 6477721737 email: shahj4@myumanitoba.ca lat: 49.8844 lon: -97.14704 hasResults: False
nctId: NCT06264622 id: CEIC-2996 briefTitle: ABG+/GarlACE Effects on Cardiovascular Risk Factors in Subjects With Grade I Hypertension acronym: GARDOSE overallStatus: RECRUITING date: 2024-02-26 date: 2024-10-31 date: 2024-12-31 date: 2024-02-20 date: 2024-02-20 name: Universitat de Lleida class: OTHER name: Pharmactive Biotech Products S.L.U briefSummary: The goal of this clinical trial is to evaluate the dose response effect on cardiovascular disease risk factors of a Black Garlic Extract in subjects with Grade I Hypertension. The main questions it aims to answer are:
Participants will be randomly assign to a low dose (250 mg/day), high dose (600 mg/day) or placebo of a standardized Garlic Extract (ABG+/GarlACE) during 12 weeks conditions: Hypertension studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 180 type: ESTIMATED name: Low dose name: High dose name: Placebo measure: Blood Pressure measure: Blood Lipid Profile sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Lleida status: RECRUITING city: Lleida zip: 25198 country: Spain name: Jose Serrano, PhD role: CONTACT phone: 973702408 email: josecarlos.serrano@udl.cat name: Manuel Portero, PhD role: CONTACT phone: 973702408 email: manuel.portero@udl.cat lat: 41.61674 lon: 0.62218 hasResults: False
nctId: NCT06264609 id: 91026 briefTitle: Precision Medicine Approach for Osteoporosis - Follow Up Study overallStatus: ENROLLING_BY_INVITATION date: 2024-02-01 date: 2029-12-31 date: 2029-12-31 date: 2024-02-20 date: 2024-02-20 name: Hartmut Malluche, MD class: OTHER briefSummary: Osteoporosis is a health problem of major proportions. It affects more than 40 million Americans and results in more than 2 million fractures annually among Medicare patients alone. Hospital admissions for osteoporotic fractures exceed those of heart attacks, strokes and breast cancer combined. Osteoporosis is commonly considered a disease associated with menopause. This estrogen deficiency related bone loss is characterized by high bone turnover with increased resorption without commensurate changes in bone formation. It is in contrast to age-related bone loss, which starts as early as in the fourth decade of life and continues with increasing age. Age-related bone loss is usually associated with lower bone turnover and decreased bone formation is the main abnormality.
Current therapies do not address age-related bone loss and the special needs of the age-related osteoporosis population is currently ignored. This is to a great degree due to difficulties associated with the bone biopsy necessary for unequivocal determination of bone turnover status. Thus, the current standard of care relies on starting with an antiresorber, which is of limited effectiveness in age-related osteoporosis, and in fact impedes the effectiveness of the appropriate anabolic medication. In a current ongoing study - Novel precision medicine approach to treatment of osteoporosis based on bone turnover. EIRB#70781; efforts are focused on addressing this particular problem.
Our follow-up study seeks to achieve one specific aim: to compare effectiveness of Alendronate vs Teriparatide after participants have been switched at the end of treatment at year one, to the other drug at year two for the same duration of treatment. conditions: Osteoporosis studyType: INTERVENTIONAL phases: PHASE4 allocation: NON_RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 40 type: ESTIMATED name: Alendronate name: Teriparatide name: Alendronate measure: Percent change in bone loss measure: Percent change in Bone Mass Density at the hip measure: Trabecular bone score (TBS) sex: FEMALE minimumAge: 45 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Kentucky city: Lexington state: Kentucky zip: 40536 country: United States lat: 37.98869 lon: -84.47772 hasResults: False
nctId: NCT06264596 id: 2310-72 briefTitle: Epinephrine in Irrigation Fluid for Visualization During Ankle Surgery overallStatus: NOT_YET_RECRUITING date: 2024-04 date: 2025-04 date: 2026-04 date: 2024-02-20 date: 2024-02-22 name: The Guthrie Clinic class: OTHER briefSummary: The purpose of this study is to evaluate the effect of epinephrine in irrigation fluid for visual clarity in ankle arthroscopic surgery. conditions: Intraoperative Bleeding studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: TRIPLE maskingDescription: Concealed irrigation bags whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR count: 78 type: ESTIMATED name: Epinephrine name: Normal Saline irrigation fluid measure: visual clarity during ankle arthroscopic surgery, which will be evaluated by visual analog scale measure: surgeon's discomfort related to bleeding, measured by visual numeric rating scale sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Robert Packer Hospital city: Sayre state: Pennsylvania zip: 18840 country: United States name: Wonyong Lee, MD role: CONTACT phone: 570-887-4882 email: Wonyong.Lee@guthrie.org name: Wonyong Lee role: PRINCIPAL_INVESTIGATOR lat: 41.97896 lon: -76.5155 hasResults: False
nctId: NCT06264583 id: IN-DE-980-6998 briefTitle: HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection overallStatus: NOT_YET_RECRUITING date: 2024-03-01 date: 2024-07-31 date: 2024-12-31 date: 2024-02-20 date: 2024-02-20 name: University Hospital, Bonn class: OTHER name: Swiss HIV Cohort Study name: ICONA Cohort name: Amsterdam UMC name: Royal Free Hospital NHS Foundation Trust name: King's College London name: University Hospital of Cologne name: Goethe University name: Heinrich-Heine University, Duesseldorf name: University Hospital, Essen name: ICH Hamburg name: Praxiszentrum Hohenstaufenring Köln name: Sorbonne University name: Henri Mondor University Hospital name: Hospital Universitario Infanta Leonor name: Hospital General Universitario Gregorio Marañon name: GEPCOI (Portuguese Group of Coinfection) briefSummary: The aim of this project is to set up a cross-sectional cohort study (France, Germany, The Netherlands, Poland, Spain, Switzerland, Italy, United Kingdom and Portugal) to assess the implementation of EACS guidelines for HDV-testing among PLWH with positive HbsAg and thereby evaluate the prevalence of HDV infection among HIV/HBV-coinfected in 2023, as well as corresponding risk factors. In addition to the testing itself, this study will also set up a cohort and databasee for future HDV studies among PLWH, including clinical, virological und laboratory parameters.
3. Define the liver disease state by APRI score, fibroscan, ultrasound and routine laboratory test results. conditions: Hepatitis D studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 8000 type: ESTIMATED name: HDV screening measure: HDV prevalence in HIV/HBV coinfection measure: Degree of liver disease in pateints with HIV/HBV/HDV triple infection sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Bonn city: Bonn state: NRW zip: 53127 country: Germany name: Jürgen Rockstroh role: CONTACT phone: +491716575969 email: juergen.rockstroh@ukbonn.de lat: 50.73438 lon: 7.09549 typeAbbrev: Prot hasProtocol: True hasSap: False hasIcf: False label: Study Protocol date: 2023-10-31 uploadDate: 2024-02-09T03:56 filename: Prot_000.pdf size: 798649 hasResults: False
nctId: NCT06264557 id: RW-MCI-01 id: ROWAN type: OTHER domain: ROWAN briefTitle: Cognitive Therapy Software for Improving Cognitive Function for Patients With Mild Cognitive Impairment acronym: SB-DEX overallStatus: RECRUITING date: 2024-01-17 date: 2024-05-31 date: 2025-05-01 date: 2024-02-20 date: 2024-02-20 name: Rowan class: INDUSTRY briefSummary: Cognitive therapy software for improving cognitive function for patients with mild cognitive impairment conditions: Mild Cognitive Impairment conditions: MCI studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 126 type: ESTIMATED name: SB-100 name: Educational book measure: K-RBANS measure: K-RBANS measure: K-MMSE-2 measure: CDR-SB measure: K-IADL measure: PRMQ measure: GDS-15 measure: QOL-AD measure: ADAS-Cog14 sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Hanyang University Guri Hospital status: RECRUITING city: Guri-si state: Gyeonggi-do zip: 11923 country: Korea, Republic of name: Hojin Choi, PI role: CONTACT lat: 37.5986 lon: 127.1394 facility: Inje University Haeundae Paik Hospital status: RECRUITING city: Busan country: Korea, Republic of name: Jinse Park, PI role: CONTACT lat: 35.10278 lon: 129.04028 facility: Inha University Hospital status: RECRUITING city: Incheon zip: 22332 country: Korea, Republic of name: Hyewon Yoon, PI role: CONTACT lat: 37.45646 lon: 126.70515 facility: Gachon University Gil Medical Center status: RECRUITING city: Incheon country: Korea, Republic of name: Kee Hyung Park, PI role: CONTACT lat: 37.45646 lon: 126.70515 facility: Chonnam National University Hospital status: RECRUITING city: Kwangju country: Korea, Republic of name: Soo Hyun Cho, PI role: CONTACT lat: 36.9122 lon: 127.1279 facility: Ewha Womans University Seoul Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Ji Young Yun, PI role: CONTACT lat: 37.566 lon: 126.9784 facility: Hanyang University Seoul Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Jin Seok Park, PI role: CONTACT lat: 37.566 lon: 126.9784 facility: Koera University Guro Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Chi Kyung Kim, PI role: CONTACT lat: 37.566 lon: 126.9784 facility: Korea University Anam Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Chan Nyoung Leee, PI role: CONTACT lat: 37.566 lon: 126.9784 facility: The Catholic University of Korea, Seoul St. Mary's Hospital status: RECRUITING city: Seoul country: Korea, Republic of name: Dong Woo Kang, PI role: CONTACT lat: 37.566 lon: 126.9784 facility: Ajou University Hospital status: RECRUITING city: Suwon country: Korea, Republic of name: Sun Min Lee, PI role: CONTACT lat: 37.29111 lon: 127.00889 facility: The Catholic University of Korea, St. Vincent's Hospital status: RECRUITING city: Suwon country: Korea, Republic of name: Yoo Hyun Um, PI role: CONTACT lat: 37.29111 lon: 127.00889 hasResults: False
nctId: NCT06264544 id: SW006 briefTitle: Trial to Evaluate the Efficacy of a Zinc, Selenium, and L-Tyrosine Supplement in the Prevention of Thyrotoxicosis in Subjects With r25191G/A SEPP1 Polymorphism acronym: ZEST-PREP overallStatus: NOT_YET_RECRUITING date: 2024-03-30 date: 2024-10-15 date: 2024-12-30 date: 2024-02-20 date: 2024-02-20 name: S.LAB (SOLOWAYS) class: OTHER name: Center of New Medical Technologies briefSummary: This randomized, double-blind, placebo-controlled trial evaluates the efficacy of a zinc, selenium, and L-tyrosine supplement in preventing thyrotoxicosis among adults aged 18-85 with elevated TPOAb levels and the r25191G/A SEPP1 polymorphism. The study excludes those with thyroid disease, pregnant/breastfeeding women, and individuals allergic to the supplement. Key endpoints include changes in thyroid antibodies and hormones over a 6-month period. With an estimated sample size of 150 participants per group, accounting for a 20% dropout rate, the trial seeks to demonstrate the supplement's potential in reducing thyrotoxicosis risk through a genetically-informed approach. conditions: Thyrotoxicosis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 150 type: ESTIMATED name: zinc, selenium, and L-tyrosine in SEPP1 name: Placebo measure: Percent change of Thyroid Peroxidase Antibodies (TPOAb) in subjects with r25191 SEPP1 polymorphism measure: Percent change in Thyroglobulin Antibodies (TgAb) in subjects with r25191 SEPP1 polymorphism measure: Free Thyroxine (Free T4) change in subjects with r25191 SEPP1 polymorphism measure: Free Triiodothyronine (Free T3) change in subjects with r25191 SEPP1 polymorphism measure: Thyroid Receptor Antibodies (TRAb) change in subjects with r25191 SEPP1 polymorphism measure: TSH Receptor Antibodies (TSHR-Ab) change in subjects with r25191 SEPP1 polymorphism sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center of New Medical Technologies city: Novosibirsk state: Novosibisk Region zip: 630090 country: Russian Federation lat: 55.0415 lon: 82.9346 hasResults: False
nctId: NCT06264531 id: JDS_2023_12 briefTitle: Efficacy and Safety of Anti-angiogenic Therapy With IV Bevacizumab in Patients With Symptomatic Cerebral Arteriovenous Malformations acronym: BevacizuMAV overallStatus: NOT_YET_RECRUITING date: 2024-06 date: 2026-12 date: 2027-06 date: 2024-02-20 date: 2024-02-22 name: Fondation Ophtalmologique Adolphe de Rothschild class: NETWORK briefSummary: Brain arteriovenous malformations (AVMs) are responsible for hemorrhagic strokes, particularly in children and young adults. They can also be responsible for chronic neurological disorders: motor or sensory deficits, disturbances of higher functions, epilepsy or disabling headaches. The management of brain AVMs is complex and requires a multidisciplinary approach in an expert center. Available therapies include endovascular embolization, neurosurgical resection and/or radiosurgery. These procedures carry a risk of neurological complications, and are reserved for small AVMs located at a distance from highly functional cerebral structures. To date, no drug therapy is recommended if interventional treatment is not possible.
Several studies on resected brain AVM tissue have demonstrated that these malformations are the site of significant evolutionary inflammatory and neo-angiogenesis processes. Other studies have specifically shown that VEGF (vascular endothelial growth factor) levels are increased in AVMs. More recently, a pre-clinical study showed that anti-angiogenic treatment with Bevacizumab reduced vascular proliferation within AVMs in mice. Finally, a Phase II clinical trial in patients with Rendu-Osler disease (a genetic vascular disorder characterized by recurrent epistaxis, cutaneous telangiectasia and the presence of visceral AVMs) showed a clinical benefit of IV Bevacizumab on the symptomatology of these vascular malformations, with a reduction in the risk of hemorrhage and the extent of hepatic arteriovenous shunts. A randomized Phase III trial is currently underway (NCT03227263) to assess the efficacy of IV Bevacizumab in Rendu-Osler disease.
The aim of our study is to assess the efficacy of IV Bevacizumab on the disabling symptoms associated with symptomatic brain AVMs. conditions: Cerebral AV Malformation studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 54 type: ESTIMATED name: Bevacizumab name: Placebo measure: Proportion of patients showing at least one of the following improvements : cognition, neurological symptoms, epilepsy symptoms, headaches. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06264518 id: 56168915 briefTitle: An Observational Exploration of Clinical Trials Targeting Traumatic Brain Injury overallStatus: NOT_YET_RECRUITING date: 2025-03 date: 2026-03 date: 2027-03 date: 2024-02-20 date: 2024-02-20 name: Power Life Sciences Inc. class: INDUSTRY briefSummary: Clinical study participation has historically been heavily biased toward specific demographics.
People with traumatic brain injury who are invited to take part in medical research will benefit from the analysis of the data. conditions: Traumatic Brain Injury studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Number of patients who decide to enroll in a traumatic brain injury clinical trial measure: Rate of patients who remain in traumatic brain injury clinical trial to trial completion sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Power Life Sciences city: San Francisco state: California zip: 94107 country: United States name: Michael B Gill role: CONTACT phone: 415-900-4227 email: https://www.withpower.com/contact-us@withpower.com lat: 37.77493 lon: -122.41942 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-09 uploadDate: 2024-02-09T11:16 filename: ICF_000.pdf size: 79118 hasResults: False
nctId: NCT06264505 id: 55955210 briefTitle: Investigative Analysis of Soft Tissue Sarcoma Clinical Trials: An Observational Study overallStatus: NOT_YET_RECRUITING date: 2025-03 date: 2026-03 date: 2027-03 date: 2024-02-20 date: 2024-02-28 name: Power Life Sciences Inc. class: INDUSTRY briefSummary: Generally, specific demographic cohorts exhibit higher participation rates in medical research, yet there exists a scarcity of research elucidating the trial attributes impacting the engagement of these particular demographics.
The primary objective of this study is to gather extensive data on the clinical trial experiences of individuals diagnosed with soft tissue sarcoma, with the aim of identifying factors hindering patient enrollment or trial completion. conditions: Soft Tissue Sarcoma studyType: OBSERVATIONAL observationalModel: CASE_CROSSOVER timePerspective: PROSPECTIVE count: 500 type: ESTIMATED measure: Rate of patients in soft tissue sarcoma clinical research measure: Number of soft tissue sarcoma study participants who maintain involvement until study finish sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Power Life Sciences city: San Francisco state: California zip: 94107 country: United States name: Michael B Gill role: CONTACT phone: 415-900-4227 email: https://www.withpower.com/contact-us@withpower.com lat: 37.77493 lon: -122.41942 typeAbbrev: ICF hasProtocol: False hasSap: False hasIcf: True label: Informed Consent Form date: 2024-02-09 uploadDate: 2024-02-09T10:34 filename: ICF_000.pdf size: 80606 hasResults: False